Johnson & Johnson (JNJ) Receives Adverse Ruling in REMICADE Patent Litigation
- Top 10 News for 12/2: Crude Rips on OPEC Cut; Starbucks' Schultz Steps Down; Nonfarm Payrolls Flat in Nov.
- Unemployment Rate Drops to 4.6%
- Bond yields slip on U.S. jobs data, euro steady before Italy vote
- Alibaba (BABA) Founder Jack Ma Discuss Plans to Retire; 'I Don't Want to Die at the Office'
- Starbucks Coffee (SBUX) CEO Howard Schultz to Step Down, Appointed Executive Chairman; Kevin Johnson New CEO
Get daily under-the-radar research with StreetInsider.com's Stealth Growth Insider Get your 2-Wk Free Trial here.
Johnson & Johnson (NYSE: JNJ) announced that the District of Massachusetts Federal Court has issued a ruling on a summary judgment motion filed by Celltrion Healthcare Co. Ltd. and Celltrion Inc. (together, Celltrion) and Hospira Healthcare Corporation (Hospira) in the infringement lawsuits related to REMICADE® (infliximab) filed by the company's subsidiary, Janssen Biotech, Inc. (Janssen).
The court issued a ruling in favor of Celltrion and Hospira, holding that U.S. Patent No. 6,284,471 for REMICADE® ('471 patent) is invalid. Janssen is disappointed with the court's ruling and plans to appeal the decision to the Court of Appeals for the Federal Circuit. Janssen is also continuing the appeal process in the proceedings related to the '471 patent before the U.S. Patent & Trademark Office, and is awaiting a date to be set for an oral hearing in the appeal.
Janssen will continue to defend its intellectual property rights relating to its innovative medicines. A commercial launch of an infliximab biosimilar prior to the outcome of the appeals would be considered an at-risk launch.
The company reaffirms its sales guidance for operational sales growth for the full-year 2016 of 3-4%, notwithstanding the possibility of a biosimilar launch on or after October 3, 2016.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Johnson & Johnson (JNJ) Receives Adverse Decision in Texas Hip Implants Case; Will Pay $1B
- Digital Ally (DGLY) Refutes TASER's Attack on ‘292 Patent; Says Nothing New Here
- Amgen (AMGN), Allergan (AGN) Announce Submission of ABP 215 MAA to EMA
Create E-mail Alert Related CategoriesCorporate News, Litigation, Management Comments
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!